Suppr超能文献

肝移植用于治疗中分化或高分化肝细胞癌。

Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma.

作者信息

Cillo Umberto, Vitale Alessandro, Bassanello Marco, Boccagni Patrizia, Brolese Alberto, Zanus Giacomo, Burra Patrizia, Fagiuoli Stefano, Farinati Fabio, Rugge Massimo, D'Amico Davide Francesco

机构信息

Clinica Chirurgica I, Dipartimento di Scienze Chirurgiche e Gastroenterlogiche, Italy.

出版信息

Ann Surg. 2004 Feb;239(2):150-9. doi: 10.1097/01.sla.0000109146.72827.76.

Abstract

OBJECTIVE

To determine the long-term results of liver transplantation for well- or moderately differentiated hepatocellular carcinoma (HCC).

SUMMARY BACKGROUND DATA

HCC patient selection for liver transplantation remains controversial, and deciding exclusively on the strength of criteria such as number and size of nodules appears prognostically inaccurate.

METHODS

Since 1991, preoperative tumor grading has been used at our center to establish whether a patient with HCC is fit for transplantation. Poorly differentiated HCC cases were excluded, while size and number of nodules were not considered as absolute selection criteria. Thirty-three patients with moderately or well-differentiated HCC were prospectively studied after liver transplantation. A group of 15 patients with incidental HCC transplanted during the same period were also evaluated and compared with the 33 patients with preoperatively diagnosed HCC.

RESULTS

On histologic examination, 38% of the entire group of 48 patients did not meet the "Milan criteria" and 42% were pTNM stages III and IV. The median follow-up was 44 months. The 5-year actuarial survival rate was 75% and recurrence-free survival was 92%. HCC recurred in only 3 patients (6%). The only histomorphologic variable differing significantly between incidental and nonincidental HCC was nodule size. The timing of diagnosis (incidental vs. nonincidental HCC), the Milan criteria, and the TNM stage revealed no statistically significant impact on overall and recurrence-free survival rates.

CONCLUSIONS

The routine pre-orthotopic liver transplantation tumor grading may represent a valid tool in the selection of unresectable HCC patients for transplantation.

摘要

目的

确定肝移植治疗高分化或中分化肝细胞癌(HCC)的长期效果。

总结背景数据

HCC患者肝移植的选择仍存在争议,仅依据结节数量和大小等标准来决定预后似乎并不准确。

方法

自1991年以来,我们中心采用术前肿瘤分级来确定HCC患者是否适合移植。排除低分化HCC病例,而结节大小和数量不作为绝对的选择标准。对33例高分化或中分化HCC患者进行肝移植术后前瞻性研究。同时评估并比较同期移植的15例意外发现HCC患者与33例术前诊断为HCC的患者。

结果

组织学检查显示,48例患者中38%不符合“米兰标准”,42%为pTNM III期和IV期。中位随访时间为44个月。5年实际生存率为75%,无复发生存率为92%。仅3例患者(6%)出现HCC复发。意外发现HCC与非意外发现HCC之间唯一有显著差异的组织形态学变量是结节大小。诊断时机(意外发现HCC与非意外发现HCC)、米兰标准和TNM分期对总体生存率和无复发生存率均无统计学显著影响。

结论

原位肝移植前常规进行肿瘤分级可能是选择不可切除HCC患者进行移植的有效工具。

相似文献

引用本文的文献

8
Clinical outcomes of patients with two small hepatocellular carcinomas.两名小肝细胞癌患者的临床结局
World J Hepatol. 2021 Oct 27;13(10):1439-1449. doi: 10.4254/wjh.v13.i10.1439.
10
Liver transplantation in malignant disease.恶性疾病中的肝移植
World J Clin Oncol. 2021 Aug 24;12(8):623-645. doi: 10.5306/wjco.v12.i8.623.

本文引用的文献

1
Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies.原发性肝癌:48900例尸检中的100例研究。
Cancer. 1954 May;7(3):462-503. doi: 10.1002/1097-0142(195405)7:3<462::aid-cncr2820070308>3.0.co;2-e.
2
Living-donor liver transplantation for hepatocellular carcinoma.肝细胞癌的活体肝移植
Transplantation. 2003 Feb 15;75(3 Suppl):S37-40. doi: 10.1097/01.TP.0000047029.02806.16.
6
Simplified staging for hepatocellular carcinoma.肝细胞癌的简化分期
J Clin Oncol. 2002 Mar 15;20(6):1527-36. doi: 10.1200/JCO.2002.20.6.1527.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验